Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications-Reference-Cited by-同舟云学术

Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications

Published:2016-04-16 Issue:1 Volume:9 Page:
ISSN:1756-8722
Container-title:Journal of Hematology & Oncology
language:en
Short-container-title:J Hematol Oncol

Author:

Pleyer Lisa,Burgstaller Sonja,Stauder Reinhard,Girschikofsky Michael,Sill Heinz,Schlick Konstantin,Thaler Josef,Halter Britta,Machherndl-Spandl Sigrid,Zebisch Armin,Pichler Angelika,Pfeilstöcker Michael,Autzinger Eva-Maria,Lang Alois,Geissler Klaus,Voskova Daniela,Geissler Dietmar,Sperr Wolfgang R.,Hojas Sabine,Rogulj Inga M.,Andel Johannes,Greil Richard

Funder

Celgene Ltd

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Molecular Biology,Hematology

Link

http://link.springer.com/content/pdf/10.1186/s13045-016-0263-4

Reference81 articles.

1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–99.

2. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835–49.

3. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Vardiman JW. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Geneva, Switzerland: WHO Press; 2008.

4. Sanz GF, Sanz MA, Vallespí T, Cañizo MC, Torrabedella M, García S, et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood. 1989;74:395–408.

5. De Rosa L, Montuoro A, Del Monte C. Myelodysplastic syndromes (MDS) with excess of blasts: identification of subgroups with different prognosis. Leuk Res. 1987;11:37.

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myeloid-derived suppressor cells: Implication in myeloid malignancies and immunotherapy;Acta Histochemica;2024-10

2. Mesenchymal stromal cells in myeloid malignancies: Immunotherapeutic opportunities;Heliyon;2024-02

3. Epigenetic modifications: Key players in cancer heterogeneity and drug resistance;Translational Oncology;2024-01

4. Application of serum Raman spectroscopy in rapid and early discrimination of aplastic anemia and myelodysplastic syndrome;Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy;2023-12

5. Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine—A prospective cohort study by the AGMT;American Journal of Hematology;2023-08-07